ANI Pharmaceuticals (ANIP) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 3.12 | 25.0 | 106.6 | 63.1 | 207.3 | 237.0 | ||
| Changes by years, y/y, % | -89% | +704% | +326% | -41% | +228% | +49.1% | |||
ANI Pharmaceuticals. EBITDA US GAAP, bln rub
ANI Pharmaceuticals. EBITDA US GAAP, changes, %
ANI Pharmaceuticals. EBITDA US GAAP, sum by quarters, bln rub
ANI Pharmaceuticals (ANIP) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | 48.4 | 39.2 | 61.2 | 76.9 | 59.6 | 237.0 | |
| Changes by years, y/y, % | +8% | +130% | -556% | +418% | +23% | |||
| Changes by quarters, q/q, % | +226% | -19% | +56% | +26% | -22% | |||